GET DAILY SIGNALSWhy Is AtriCure (ATRC) Stock Down -2.84% Today?
Key Takeaways
- Shares of ATRC were down roughly 2.84% in Thursday's session, easing to about $59.54 from a prior close of $61.28.
- The pullback follows a sharp post-earnings surge, suggesting investors are locking in gains after a double-digit run-up earlier in the week.
- Third-quarter results released on November 3 beat expectations, with revenue of $154.5 million and a surprise profit versus a projected loss.
- Several analysts raised their price targets on the stock, including BTIG, Piper Sandler, and Canaccord, even as the shares retreated.
- A disclosed insider sale by the company's chief technology officer under a pre-arranged 10b5-1 plan added a modest overhang to sentiment.
- Traders are watching whether the stock can hold recent technical support and how the broader healthcare sector trades into the close.
- For more detail on Price Targets, Earnings, and Forecast, explore the dedicated pages for this ticker.
- You can also discover active trading strategies on Tickeron's Trending AI Robots page.
Opening Summary
AtriCure, Inc. (ATRC), a medical-device innovator specializing in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, traded lower on Thursday. The stock was down about 2.84% in the session, easing to roughly $59.54 after closing the prior session at $61.28. The decline marked a continuation of a give-back from an earlier post-earnings rally, with markets attributing the move primarily to profit-taking following strong third-quarter results and a wave of analyst price-target increases.
Profit-Taking After a Post-Earnings Surge
The most immediate catalyst behind Thursday's decline was a classic "sell the news" reaction. AtriCure reported third-quarter 2026 results after the close on November 3, posting worldwide revenue of $154.5 million, a 15.0% year-over-year increase that topped Wall Street estimates of roughly $151.15 million. The company also swung to profitability, reporting net income of $4.1 million and adjusted EBITDA of $26.8 million, with non-GAAP earnings per share of $0.18 well ahead of the consensus expectation for a loss.
The beat triggered an initial price rally that pushed shares sharply higher the following day. With the stock having surged toward its 52-week high, momentum stalled and traders began taking profits. Thursday's decline reflects that continued unwinding, as short-term buyers booked gains rather than chase the stock at elevated levels.
Analyst Reactions: Upgrades Met With Caution
Wall Street responded favorably to the quarterly report, with multiple firms raising their price targets. BTIG lifted its target to $70 while maintaining a Buy rating, Piper Sandler raised its target to $70 from $60 with an Overweight rating, and Canaccord boosted its target to $67 from $55. Analysts pointed to the top-and-bottom-line beat and improved profitability guidance as key positives.
Despite the bullish revisions, the market reaction underscores a common dynamic: after a stock has already rallied strongly into and immediately after an earnings event, even positive analyst commentary can be insufficient to sustain further upside in the near term. The earnings-driven move upward simply ran out of fresh buyers, allowing the shares to consolidate lower.
Insider Selling Adds to the Overhang
A separate disclosure added a layer of caution to the tape. Regulatory filings showed that Salvatore Privitera, AtriCure's chief technology officer, sold 8,404 shares on November 4 at $65.00 per share, a transaction valued at roughly $546,260. The sale was executed under a pre-established 10b5-1 trading plan adopted earlier in the year, meaning it was scheduled in advance rather than a reaction to current conditions. Even so, insider selling near a 52-week high can weigh on retail sentiment and contributed to the cautious tone surrounding the stock.
Market Context and Trading Activity
AtriCure's move came against a backdrop of heightened volatility in the name following its earnings release. Daily trading volume picked up meaningfully around the report, reflecting elevated participation as investors repositioned. The pullback also aligned with the stock's broader technical picture: after breaking to new highs, shares retreated toward levels that previously acted as support, a pattern consistent with a healthy consolidation rather than a fundamental deterioration.
Within the healthcare and medical-device space, sentiment remained mixed, with sector peers exhibiting similar bouts of post-earnings choppiness. The decline in ATRC appeared to be more company- and momentum-specific than a broad-based sector selloff, given the concentration of the move around the earnings and insider-sale headlines.
What Comes Next for ATRC
Looking ahead, investors will monitor whether AtriCure can hold onto its improved profitability trajectory and sustain double-digit revenue growth. Management raised the midpoint of its revenue guidance and lifted the low end of its full-year outlook, signaling confidence in demand across its cardiac-surgery portfolio.
Clinical catalysts also remain in focus. The company continues to advance its BoxX-NoAF trial, which is evaluating ablation and LAA management in cardiac-surgery patients without a history of Afib, with enrollment nearing completion and initial primary-endpoint data expected in 2027. Risks include potential reimbursement changes, competitive dynamics in the medical-device market, and the possibility of further insider or institutional selling as the stock consolidates. While near-term momentum has cooled, the fundamental backdrop remains supported by solid execution and a constructive analyst consensus.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots drawn from a broader lineup of hundreds of bots covering thousands of tickers. Only the strongest performers under current market conditions are featured, with each bot varying by strategy, timeframe, performance metrics, and the symbols it trades. Exploring this page can help traders identify automated strategies aligned with today's market environment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
Aroon Indicator for ATRC shows an upward move is likely
ATRC's Aroon Indicator triggered a bullish signal on November 06, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 244 similar instances where the Aroon Indicator showed a similar pattern. In 182 of the 244 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 75%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +9.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where ATRC advanced for three days, in 212 of 301 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
Bearish Trend Analysis
The 10-day RSI Indicator for ATRC moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 25 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 83%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 47 of 62 cases where ATRC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 76%.
The Momentum Indicator moved below the 0 level on November 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ATRC as a result. In 74 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for ATRC turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 40 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATRC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
ATRC broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. ATRC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.766) is normal, around the industry mean (4.955). ATRC's P/E Ratio (266.091) is considerably higher than the industry average of (40.806). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (4.869) is also within normal values, averaging (56.876).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATRC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of surgical and medical instruments
Industry PharmaceuticalsOther
Advertisement